Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

HSE Warns Employers To Safeguard Employees After Worker Suffers Double-Fracture To Finger, UK
The Health and Safety Executive (HSE) is warning employers to ensure they have adequate safeguards in place to prevent access to dangerous parts of their machinery. This warning follows HSE"s prosecution of Metal Containers Ltd (formerly trading as Greif UK Ltd) after an employee"s one finger was broken in two places and another injured in the unguarded rotating part of a chained conveyor.
generic viagra online
What Is Diphtheria? What Causes Diphtheria?
Diphtheria is a bacterial infection in the upper respiratory tract. Typically it is characterized by sore throat, swollen neck glands, high temperature and breathing difficulties. Through means of successful immunization diphtheria is now very rare in the United States and Europe. However it"s still common in countries where immunization programs are not an integral part of standard public health care. It is a potentially fatal disease with an estimated 5-10% fatality rate. In children under 5 and adults over 40 the fatality rate may sometimes reach 20%.
News of the day
One In Six Public Health Workers Won't Work In Emergency Flu Pandemic, According To Ben-Gurion University Of The Negev Researchers
A study conducted by researchers at Ben-Gurion University of the Negev (BGU) and John Hopkins Bloomberg School of Public Health indicates that approximately 16 percent of public health care workers will not report for work in a pandemic flu emergency, regardless of the severity.
Diagnostics

Breakthrough In The Development Of A Novel Human Antibody Platform Announced By OMT

Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, have announced the creation of the first targeted knockout rats as detailed in "Knockout Rats Produced via Embryo Microinjection of Designed Zinc Finger Nucleases," published in the July 24th issue of Science. The creation of rats with permanent, heritable genetic mutations is a critical milestone in the development of OMT"s novel human monoclonal antibody platform. "Creating a knockout rat was the biggest challenge OMT faced", said Dr. Roland Buelow, CEO of OMT and senior author of the paper. "Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To solve this problem, we explored a new application for Zinc Finger Nuclease (ZFN) technology, which enabled a technique that could revolutionize the genetic engineering of animals." In the study, OMT scientists and its collaborators used ZFNs developed by Sangamo BioSciences, Inc. to knockout a gene encoding rat immunoglobulin. The mutations in rat immunoglobulin caused no off-target effects in other genes, and offspring of the ZFN-edited rats carried the mutated genes. Together, these results demonstrate the ability to generate heritable, specific and permanent modifications in a mammal using standard microinjection techniques and engineered ZFNs in early-stage embryos. With antibody sales expected to reach $50 billion within five years, many companies have entered the biologics market through acquiring antibody technologies or licensing/fee for service arrangements. Currently, the mouse is the only genetically engineered animal commercially available for the generation of human monoclonal antibodies, and many targets are licensed already. The expense and limitations of the mouse technology create an opportunity for OMT and its new monoclonal antibody platform with unrestricted development options. OMT"s human antibody technology is the result of an improved understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression described in the Science article. Previously, it took either embryonic stem cells or nuclear transfer cloning -- techniques that are not available for the genetic engineering of rats - to create a knockout, OMT used a new ZFN-mediated technique to generate immunoglobulin knockout rats. ZFNs are engineered proteins that induce double-strand breaks at specific sites in an organism"s DNA. Such double-strand breaks stimulate the cell"s natural DNA-repair pathways and can result in site- specific changes in the DNA sequence. Up to now, ZFNs have been used to edit specific genes in fruit flies, worms (C. elegans), cultured cells and zebrafish embryos, but this is the first example of successful, permanent, heritable gene-editing in a mammal. Dr. Roland Buelow Open Monoclonal Technology, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009